stoxline Quote Chart Rank Option Currency Glossary
Aptose Biosciences Inc. (APTO)
1.14  0 (0%)    05-30 14:31
Open: 1.13
High: 1.17
Volume: 35,559
Pre. Close: 1.14
Low: 1.1
Market Cap: 19(M)
Technical analysis
2024-05-30 2:42:21 PM
Short term     
Mid term     
Targets 6-month :  1.38 1-year :  1.48
Resists First :  1.18 Second :  1.26
Pivot price 1.16
Supports First :  1.05 Second :  0.88
MAs MA(5) :  1.12 MA(20) :  1.17
MA(100) :  1.61 MA(250) :  2.72
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  40.7 D(3) :  34
RSI RSI(14): 39.7
52-week High :  6.59 Low :  0.4
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ APTO ] has closed above bottom band by 35.8%. Bollinger Bands are 50.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.16 - 1.17 1.17 - 1.17
Low: 1.09 - 1.09 1.09 - 1.1
Close: 1.13 - 1.14 1.14 - 1.15
Company Description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Headline News

Wed, 29 May 2024
Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at - Defense World

Tue, 14 May 2024
Aptose Reports Results for the First Quarter 2024 - GlobeNewswire

Tue, 14 May 2024
Aptose Biosciences Inc. (APTO) Q1 2024 Earnings Call Transcript - Seeking Alpha

Sat, 11 May 2024
Aptose Biosciences (APTO) Stock Forecast and Price Target 2024 - MarketBeat

Fri, 05 Apr 2024
What Makes Aptose Biosciences (APTO) a New Buy Stock - Yahoo Finance

Wed, 27 Mar 2024
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 16 (M)
Shares Float 13 (M)
Held by Insiders 19 (%)
Held by Institutions 8.1 (%)
Shares Short 84 (K)
Shares Short P.Month 86 (K)
Stock Financials
EPS -7.58
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.38
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -102.3 %
Return on Equity (ttm) -294 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.22
Qtrly Earnings Growth 0 %
Operating Cash Flow -45 (M)
Levered Free Cash Flow -26 (M)
Stock Valuations
PE Ratio -0.16
PEG Ratio 0
Price to Book value -3.09
Price to Sales 0
Price to Cash Flow -0.42
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android